Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ECC 2015: Rare Cancer Activities & Highlights

ECC 2015: Rare Cancer Activities
Start date
25 Sep 2015
End date
29 Sep 2015
Vienna, Austria

Three ECC 2015 sessions with a focus on rare cancers

Paediatric Oncology Society Session: European Society for Pediatric Oncology (SIOPE)

26 Sept 10:30-12:30

  • Chair: G. Vassal (France) 
  • Co-Chair: M. Schrappe (Germany)

10:30: Introduction of the session

  • Speaker: M. Schrappe (Germany)

10:35: Presentation of the Lifetime Achievement Award

  • Speaker: G. Vassal (France)

10:40: Lifetime Achievement Award Presentation

  • Speaker: H.F. Jürgens (Germany)

10:55: Merit Award Presentation

Speaker: R. Hill (United Kingdom)

11:10: Future of paediatric oncology

  • Speaker: G. Vassal (France)

11:35: Improving radiotherapy for children and adolescents

  • Speaker: T. Boterberg (Belgium)

12:00: Maximising the opportunities from a very rare tumour portfolio: the siopel experience

  • Speaker: B. Morland (United Kingdom)

12.25: Take home message

  • Speaker: M. Schrappe (Germany) 

Oncopolicy Forum: Tackling Rare Cancers Requiring Specialist Care: European Reference Networks

28 Sept 17:00 - 18:30

  • Chair: P.G. Casali (Italy)

17:15: The patient perspective

  • Speaker: J. Geissler (Germany)

17:30: The research perspective: SPECTARARE

  • Speaker: D. Lacombe (Belgium)

17:45: Spotlight on ERN in paediatric cancer: ExPO-r-Net

  • Speaker: R. Ladenstein (Austria)

18:00: Views from the policy makers' perspective

  • Speaker: T. Voigtlaender (Austria) 

Questions from the audience


Scientific Symposium: Bayesian, Adaptive and Rare Disease Designs

29 Sept 09:00 - 10:30

  • Chair: U. Dafni (Greece)
  • Co-Chair: B. Ryll (Sweden)

09:00: Design in rare disease: The oncologist perspective

  • Speaker: P.G. Casali (Italy)

09:20: Implementing innovative trial design in small patient populations in childhood cancers

  • Speaker: K. Wheatley (United Kingdom)

09:40: Pitfalls and advantages of using adaptive trial designs in phase III trials

  • Speaker: M. Mauer (Belgium)

10:00: Multi-arm, multi-stage designs: Are they deliverable?

  • Speaker: M. Parmar (United Kingdom)

Discussion & Roundup

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.